

July 16, 2022

National Stock Exchange of India Limited Listing Department, Bandra Kurla Complex, Mumbai- 400 051 Scrip code: ORCHIDPHAR	BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 524372
--	---

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Approval of application under the Production Linked Incentive (PLI) Scheme filed by Orchid Bio-Pharma Limited, a Wholly owned Subsidiary of Orchid Pharma Limited

Dear Sir/Mam

With reference to the captioned subject, we would like to apprise you that the Company's Wholly Owned Subsidiary in India namely Orchid Bio-Pharma Limited ("Wholly Owned Subsidiary") had made an application with the Competent Authority under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India.

We are pleased to inform all our Stakeholders that approval has been accorded by IFCI Limited vide its letter bearing reference IFCI/CASD/DoP/PLI220715016 to the Wholly Owned Subsidiary for manufacture of the product "7 ACA" with a committed capacity of 1000 Metric Tonne Per Annum. This approval will help the Company in backward integration, reduce dependency on sourcing from China and aid in improving margins.

Kindly take the above information on records.

Thanking you,

For **Orchid Pharma Limited**



Nikita K
Company Secretary